Human Genome Epidemiology Literature Finder
Records 1 - 10 (of 10 Records) |
Query Trace: Neutropenia and UGT1A9[original query] |
---|
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 11 (3): 1226-36. Carlini Leslie E, Meropol Neal J, Bever John, Andria Michael L, Hill Todd, Gold Philip, Rogatko Andre, Wang Hao, Blanchard Rebecca |
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 May 24 (15): 2237-44. Han Ji-Youn, Lim Hyeong-Seok, Shin Eun Soon, Yoo Yeon-Kyeong, Park Yong Hoon, Lee Jong-Eun, Jang In-Jin, Lee Dae Ho, Lee Jin S |
Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2009 Jan 63 (1): 115-20. Han Ji-Youn, Lim Hyeong-Seok, Park Yong Hoon, Lee Sung Young, Lee Jin S |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. British journal of cancer 2010 Aug 103 (4): 581-9. Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano J L, Moreno |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. The Tohoku journal of experimental medicine 2013 229 (2): 107-14. Inoue Kazuyuki, Sonobe Momoyo, Kawamura Yukinori, Etoh Takashi, Takagi Masakazu, Matsumura Takashi, Kikuyama Masataka, Kimura Midori, Minami Sato, Utsuki Hiroaki, Yamazaki Tomoaki, Suzuki Takayo, Tsuji Daiki, Hayashi Hideki, Itoh Kunihi |
XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer. Oncology letters 2014 Oct 8 (4): 1864-1872. Cui Chengxu, Shu Chang, Yang Yi, Liu Junbao, Shi Shuping, Shao Zhujun, Wang Nan, Yang Ting, Hu Songni |
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens. Oncology letters 2016 Nov 12 (5): 4231-4237. Cui Chengxu, Shu Chang, Cao Dandan, Yang Yi, Liu Junbao, Shi Shuping, Shao Zhujun, Wang Nan, Yang Ting, Liang Hao, Zou Shanshan, Hu Songni |
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L |
Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients. Clinical drug investigation 2018 Sep . Kiang Tony K L, Partovi Nilufar, Shapiro R Jean, Berman Jacob M, Collier Abby C, Ensom Mary H |
The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & informatics 2022 Sep 20 (3): e29. Lee Choong-Kun, Chon Hong Jae, Kwon Woo Sun, Ban Hyo-Jeong, Kim Sang Cheol, Kim Hyunwook, Jeung Hei-Cheul, Chung Jimyung, Rha Sun You |
- Page last reviewed:Feb 1, 2024
- Content source: